Press Release
Category Added in a WPeMatico Campaign
-
BioMarin Announces Board Leadership Transition
Ian T. Clark elected Chair of the Board; Richard A. Meier to retire SAN RAFAEL, Calif., April 21, 2026 /PRNewswire/ —…
Read More » -
BRIDGE Appoints Morgan Jetto As Executive Vice President, Business Development & Ecosystems
Industry Veteran to Lead Strategic Partnerships as BRIDGE Extends Its Position as the Trusted Partner for Audience Targeting, Curation, and…
Read More » -
Collaboration Connects Early Autism Diagnosis with High-Quality, Outcomes-Driven Care Amid Industry-Wide Access Issues
WALNUT CREEK, Calif. and NEWPORT BEACH, Calif. , April 21, 2026 /PRNewswire/ — In a strategic move that unites one of…
Read More » -
800 Pound Gorilla Launches Gorilla Comedy+ Streaming Service with Cineverse
Launching May 5, Gorilla Comedy+ Will Feature New Stand-Up Specials From Patton Oswalt, Pete Holmes, Jourdain Fisher, Emmy Blotnick, Nish…
Read More » -
SWEP Expands Heat Transfer Offering Through New Strategic Partnership
DOWNERS GROVE, Ill., April 21, 2026 /PRNewswire/ — SWEP, part of Dover (NYSE: DOV) and a world-leading supplier of brazed…
Read More » -
Johnson Controls Announces Second Quarter 2026 Earnings Conference Call Webcast and “Going to Gemba Day” for Investors and Sell-Side Analysts
CORK, Ireland, April 21, 2026 /PRNewswire/ — Johnson Controls International plc (NYSE: JCI), a global technology leader in energy efficiency,…
Read More » -
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ — BioLife Solutions,…
Read More » -
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
DUBLIN, April 21, 2026 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter…
Read More » -
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and…
Read More »